IART Healthcare

Integra LifeSciences Holdings Corporation

$13.63+0.15%

Price as of close on Nov 3, 2026 · Financials updated Oct 9, 2026

Basics

Sector: Healthcare
Industry: Medical Devices
Country: United States
Market cap: 1.1B USD
Enterprise value: 1.5B USD
Full-time employees: 4,427

Overall health

Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 1.21 vs a peer median of 0.63) and more debt relative to equity (0.68× vs a peer median of 0.22×)higher risk: bigger price swings (beta 1.21 vs peers 0.63) and more debt vs equity (0.68× vs peers 0.22×)
About average: profitability and growth

Ranks #777 of 1,157 healthcare companies (bottom 33%)

See how it ranks against its peers

Worth knowing

Returning more cash than it generates. Paid out $328M vs $67M of free cash flow over the 3 fiscal years to 2025.
Integra LifeSciences returned $328M to shareholders over three years, 489% of the free cash flow it produced. That gap has to be covered by cash reserves or new debt, which can't last indefinitely.
Valuation signals disagree. Cheaper than 85% of peers on operating cash profit (EBITDA), but only 0% on earnings.Cheaper than 85% of peers on operating cash profit, but only 0% on earnings.
Relative to its operating cash profit (EBITDA), Integra LifeSciences looks cheaper than 85% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.Relative to its operating cash profit, Integra LifeSciences looks cheaper than 85% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Loss over 12 months, profit last quarter. Lost money in the 12 months to June 2026, but made a $4.5M profit in the quarter to June 2026.
Integra LifeSciences reported a net loss over the last twelve months, but its most recent quarter was profitable ($4.5M). One quarter isn't a trend, but it's closer to profitability than the 12-month figure suggests.

StockQuotient Score

43/ 100

Oct 5 43 → Nov 4 43

Valuation

Is the price right?

60/100

Moderate▼ 2 since Oct 27 close

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why it changed since the Oct 27, 2026 close: Score 62 → 60

Share price +13.7%-4
Company's reported figures updated+2

Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.

Why

Stronger than most peers on:

▲ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-0.7%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield11.2%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsReported value50% base weight · Z-score 1.79Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield2.4%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingReported value20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield98.4%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

42/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Held back by:

▼ Revenue growth
▼ 3-yr revenue

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Still loss-making, but the loss per share narrowed33% base weight · Z-score 0.29Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth2.2%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score -0.44Sector median: 0.0584 · MAD: 0.0840

Revenue growth1.6%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -0.46Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

42/100

Moderate▲ 1 since Oct 27 close

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

Operating margin rose 32.3 points to 4.0%

Why it changed since the Oct 27, 2026 close: Score 41 → 42

Peer companies moved+1

Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.

Why

Close to the peer norm on every measure.

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin4.0%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -0.25Sector median: 0.0706 · MAD: 0.1217

Return on assets-0.2%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -0.35Sector median: 0.0166 · MAD: 0.0537

Return on invested capital3.4%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -0.13Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin52.5%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-0.7%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Beta
▼ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta1.21

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -1.73Sector median: 0.6250 · MAD: 0.3380

Current ratio3.60×

SEC filings · latest balance sheetReported value33% base weight · Z-score 0.73Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.68×

SEC filings · latest balance sheetReported value33% base weight · Z-score -2.24Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Integra LifeSciences

Is Integra LifeSciences getting weaker?: Its latest SEC filing (Jul 29, 2026) got stronger: operating margin rose 32.3 points to 4.0%. Its overall score is unchanged at 43/100 since Oct 28, 2026.
How is Integra LifeSciences valued vs its peers?: Priced lower than most peers relative to what it earns. Valuation scores 60/100 against 1,393 healthcare peers. EBITDA yield 11.2% vs a peer median of 4.0% (stronger than 85% of peers).EBITDA yield 11.2% vs peers 4.0% (stronger than 85% of peers). Earnings yield -0.7% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -0.7% vs peers 1.5% (weaker than 100% of peers).
Is Integra LifeSciences growing?: At about the same pace as its peers. Growth scores 42/100 against 1,393 healthcare peers. Revenue growth 1.6% vs a peer median of 6.1% (weaker than 66% of peers).Revenue growth 1.6% vs peers 6.1% (weaker than 66% of peers).
How profitable is Integra LifeSciences?: About as profitable as its peers. Profitability scores 42/100 against 1,393 healthcare peers.
How risky is Integra LifeSciences?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 3.60× vs a peer median of 2.59× (stronger than 62% of peers).Current ratio 3.60× vs peers 2.59× (stronger than 62% of peers). Beta 1.21 vs a peer median of 0.63 (weaker than 80% of peers).Beta 1.21 vs peers 0.63 (weaker than 80% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Jul 29, 2026 · compared with the quarter ended Mar 31, 2026

Got stronger

Operating margin rose 32.3 points to 4.0%

	Previous quarter	Latest quarter	Change
Revenue (12 months)	1.6B USD	1.6B USD	+0.2%
Net income (12 months)	−496.1M USD	−7.6M USD	−98.5%
Operating margin	-28.4%	4.0%	+32.3 pts
Free cash flow (12 months)	4.1M USD	25.8M USD	+532.4%
Debt	716.9M USD	707.2M USD	−1.4%
Cash	236.8M USD	214.4M USD	−9.5%
Shares outstanding	77.8M	77.8M	−0.0%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Medical Devices · 33 companies

Valuations in Medical Devices are near the bottom of their range since 2016.

7% of months since 2016 were valued lower than now.
4% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values −8% and earnings +33% (medians): earnings grew faster than prices.
Median price-to-sales is +20% vs the whole market, against a usual +109%.

2016Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	—	—	—	—	—	—
Operating margin	12.8%	15.3%	7.2%	1.8%	-30.2%	▼ 32 pts
Net margin	11.0%	11.6%	4.4%	-0.4%	-31.6%	▼ 31 pts
Return on assets (ROA)	4.5%	4.6%	1.8%	-0.2%	-14.3%	▼ 14 pts
Return on equity (ROE)	10.0%	10.0%	4.3%	-0.4%	-49.5%	▼ 49 pts
Free cash flow margin	17.1%	14.3%	4.7%	1.6%	-1.9%	▼ 3.4 pts
Current ratio	3.39×	3.62×	3.45×	1.17×	2.54×	▲ 117%
Quick ratio	2.46×	2.61×	2.18×	0.71×	1.46×	▲ 107%
Debt to equity	0.50×	0.43×	0.49×	0.49×	0.70×	▲ 41%
Interest coverage	3.91×	4.82×	2.17×	0.40×	-5.72×	▼ >999%

IART price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 1.21 vs a peer median of 0.63) and more debt relative to equity (0.68× vs a peer median of 0.22×)higher risk: bigger price swings (beta 1.21 vs peers 0.63) and more debt vs equity (0.68× vs peers 0.22×)

About average: profitability and growth

Ranks #777 of 1,157 healthcare companies (bottom 33%)

See how it ranks against its peers

Worth knowing

Returning more cash than it generates. Paid out $328M vs $67M of free cash flow over the 3 fiscal years to 2025.

Integra LifeSciences returned $328M to shareholders over three years, 489% of the free cash flow it produced. That gap has to be covered by cash reserves or new debt, which can't last indefinitely.

Valuation signals disagree. Cheaper than 85% of peers on operating cash profit (EBITDA), but only 0% on earnings.Cheaper than 85% of peers on operating cash profit, but only 0% on earnings.

Relative to its operating cash profit (EBITDA), Integra LifeSciences looks cheaper than 85% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.Relative to its operating cash profit, Integra LifeSciences looks cheaper than 85% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Loss over 12 months, profit last quarter. Lost money in the 12 months to June 2026, but made a $4.5M profit in the quarter to June 2026.

Integra LifeSciences reported a net loss over the last twelve months, but its most recent quarter was profitable ($4.5M). One quarter isn't a trend, but it's closer to profitability than the 12-month figure suggests.

Questions investors ask about Integra LifeSciences

Is Integra LifeSciences getting weaker?

Its latest SEC filing (Jul 29, 2026) got stronger: operating margin rose 32.3 points to 4.0%. Its overall score is unchanged at 43/100 since Oct 28, 2026.

How is Integra LifeSciences valued vs its peers?

Priced lower than most peers relative to what it earns. Valuation scores 60/100 against 1,393 healthcare peers. EBITDA yield 11.2% vs a peer median of 4.0% (stronger than 85% of peers).EBITDA yield 11.2% vs peers 4.0% (stronger than 85% of peers). Earnings yield -0.7% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -0.7% vs peers 1.5% (weaker than 100% of peers).

Is Integra LifeSciences growing?

At about the same pace as its peers. Growth scores 42/100 against 1,393 healthcare peers. Revenue growth 1.6% vs a peer median of 6.1% (weaker than 66% of peers).Revenue growth 1.6% vs peers 6.1% (weaker than 66% of peers).

How profitable is Integra LifeSciences?

About as profitable as its peers. Profitability scores 42/100 against 1,393 healthcare peers.

How risky is Integra LifeSciences?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 3.60× vs a peer median of 2.59× (stronger than 62% of peers).Current ratio 3.60× vs peers 2.59× (stronger than 62% of peers). Beta 1.21 vs a peer median of 0.63 (weaker than 80% of peers).Beta 1.21 vs peers 0.63 (weaker than 80% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

1.6B USD

1.6B USD

+0.2%

Net income (12 months)

−496.1M USD

−7.6M USD

−98.5%

Operating margin

-28.4%

4.0%

+32.3 pts

Free cash flow (12 months)

4.1M USD

25.8M USD

+532.4%

Debt

716.9M USD

707.2M USD

−1.4%

Cash

236.8M USD

214.4M USD

−9.5%

Shares outstanding

77.8M

77.8M

−0.0%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

—

Operating margin

12.8%

15.3%

7.2%

1.8%

-30.2%

▼ 32 pts

Net margin

11.0%

11.6%

4.4%

-0.4%

-31.6%

▼ 31 pts

Return on assets (ROA)

4.5%

4.6%

1.8%

-0.2%

-14.3%

▼ 14 pts

Return on equity (ROE)

10.0%

4.3%

-0.4%

-49.5%

▼ 49 pts

Free cash flow margin

17.1%

14.3%

4.7%

1.6%

-1.9%

▼ 3.4 pts

Current ratio

3.39×

3.62×

3.45×

1.17×

2.54×

▲ 117%

Quick ratio

2.46×

2.61×

2.18×

0.71×

1.46×

▲ 107%

Debt to equity

0.50×

0.43×

0.49×

0.70×

▲ 41%

Interest coverage

3.91×

4.82×

2.17×

0.40×

-5.72×

▼ >999%